Lilly to buy Calytrix Bio for up to $1.5 billion

By Reuters News

- Eli Lilly LLY.N has agreed to acquire Calytrix Bio for up to $1.5 billion in cash to expand the development of treatments for rare blood cancers, the privately held biotech said on Monday.

The move is the latest in a string of acquisitions by the Indianapolis-based pharmaceutical giant as it works to diversify beyond its blockbuster diabetes and weight-loss franchise, the company's primary growth engine.

https://www.reuters.com/graphics/LILLY-DEALS/LILLY-DEALS/byprnyrzdpe/chart.png

The Calytrix transaction includes an upfront payment and additional payments tied to clinical trial and regulatory milestones. Calytrix did not disclose the size of the upfront payment or the deal's expected closing date.

Calytrix's lead candidate is an early-stage antibody treatment for essential thrombocythemia and myelofibrosis – rare blood disorders that cause the bone marrow to produce excessive abnormal blood cells.

The deal is expected to strengthen Lilly's footprint in hematology, adding an experimental treatment to a business that already includes the FDA-approved blood cancer medicine Jaypirca.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk